Literature DB >> 25822432

Diagnostic accuracy of controlled attenuation parameter measured by transient elastography for the non-invasive assessment of liver steatosis: a prospective study.

Monica Lupșor-Platon1, Diana Feier2, Horia Stefănescu3, Attila Tamas2, Emil Botan4, Zeno Sparchez3, Anca Maniu2, Radu Badea2.   

Abstract

BACKGROUND AND AIMS: A novel non-invasive tool based on the evaluation of ultrasound attenuation using transient elastography (TE) has been developed, called controlled attenuation parameter (CAP). We aim to establish the histopathological parameters that significantly influence CAP, the cutoff values and their performance in predicting each steatosis grade on a group of biopsied patients with chronic liver diseases (CLD) from Romania.
METHODS: We prospectively analyzed 201 consecutive CLD patients who underwent CAP measurements using TE. Steatosis, liver fibrosis and necroinflammatory activity were staged and graded during the pathological analysis of bioptic specimens. Univariate and multivariate regression analyses were applied to identify the variables correlated with CAP values. The diagnostic performance of CAP for steatosis prediction was assessed using an AUC analysis.
RESULTS: Among the histopathological factors correlating with CAP, the multivariate analysis found steatosis as the only factor independently influencing CAP values (p < 0.001). Maximal diagnostic accuracy (DA) was obtained for the prediction of ≥ 34-66% (S2) fatty load and of 67-100% (S3) fatty load (82.06%, respectively 81.59%) while, for the prediction of ≥ 11-33% (S1) fatty load, DA reached only 76.11%. The negative predictive value for the exclusion of ≥ S2 and S3 was 93.5% and 98.7%, respectively. AUCs calculated between each two steatosis grades were: 0.772 (S0 vs S1), 0.874 (S0 vs S2), 0.904 (S0 vs S3), 0.659 (S1 vs S2), 0.777 (S1 vs S3), and 0.665 (S2 vs S3).
CONCLUSION: Steatosis is the only histopathological factor independently influencing CAP. Maximal DA could be obtained for the prediction of ≥ S2 and S3 (82.06% and 81.59%), while for the prediction of S1, the accuracy reached only 76.11%.

Entities:  

Mesh:

Year:  2015        PMID: 25822432     DOI: 10.15403/jgld.2014.1121.mlp

Source DB:  PubMed          Journal:  J Gastrointestin Liver Dis        ISSN: 1841-8724            Impact factor:   2.008


  14 in total

Review 1.  Noninvasive assessment of alcoholic liver disease using unidimensional transient elastography (Fibroscan(®)).

Authors:  Monica Lupsor-Platon; Radu Badea
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

2.  Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population.

Authors:  Wah-Kheong Chan; Nik Raihan Nik Mustapha; Grace Lai-Hung Wong; Vincent Wai-Sun Wong; Sanjiv Mahadeva
Journal:  United European Gastroenterol J       Date:  2016-06-23       Impact factor: 4.623

Review 3.  Transient elastography (FibroScan(®)) with controlled attenuation parameter in the assessment of liver steatosis and fibrosis in patients with nonalcoholic fatty liver disease - Where do we stand?

Authors:  Ivana Mikolasevic; Lidija Orlic; Neven Franjic; Goran Hauser; Davor Stimac; Sandra Milic
Journal:  World J Gastroenterol       Date:  2016-08-28       Impact factor: 5.742

4.  Effect of Meal Ingestion on Liver Stiffness and Controlled Attenuation Parameter.

Authors:  Marco Silva; Pedro Costa Moreira; Armando Peixoto; Ana Luísa Santos; Susana Lopes; Regina Gonçalves; Pedro Pereira; Hélder Cardoso; Guilherme Macedo
Journal:  GE Port J Gastroenterol       Date:  2018-04-20

5.  NON-INVASIVE ASSESSMENT OF LIVER STEATOSIS AND FIBROSIS USING TRANSIENT ELASTOGRAPHY AND CONTROLLED ATTENUATION PARAMETER IN TYPE 2 DIABETES PATIENTS.

Authors:  A Sima; I Sporea; R Timar; M Vlad; A Braha; A Popescu; S Nistorescu; R Mare; R Sirli; A Albai; O Albai; L Diaconu; T Sorescu; S Popescu; L Sima
Journal:  Acta Endocrinol (Buchar)       Date:  2018 Jul-Sep       Impact factor: 0.877

6.  Diagnostic Accuracy of Controlled Attenuation Parameter for Detecting Hepatic Steatosis in Patients with Chronic Liver Disease.

Authors:  Patrícia Andrade; Susana Rodrigues; Eduardo Rodrigues-Pinto; Rui Gaspar; Joanne Lopes; Susana Lopes; Guilherme Macedo
Journal:  GE Port J Gastroenterol       Date:  2016-12-23

7.  Quantification of Liver Fibrosis, Steatosis, and Viscosity Using Multiparametric Ultrasound in Patients with Non-Alcoholic Liver Disease: A "Real-Life" Cohort Study.

Authors:  Alexandru Popa; Felix Bende; Roxana Șirli; Alina Popescu; Victor Bâldea; Raluca Lupușoru; Radu Cotrău; Renata Fofiu; Camelia Foncea; Ioan Sporea
Journal:  Diagnostics (Basel)       Date:  2021-04-26

8.  Lobeglitazone, a Novel Thiazolidinedione, Improves Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes: Its Efficacy and Predictive Factors Related to Responsiveness.

Authors:  Yong Ho Lee; Jae Hyeon Kim; So Ra Kim; Heung Yong Jin; Eun Jung Rhee; Young Min Cho; Byung Wan Lee
Journal:  J Korean Med Sci       Date:  2017-01       Impact factor: 2.153

9.  Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease.

Authors:  Hye Won Lee; Soo Young Park; Seung Up Kim; Jae Young Jang; Hana Park; Ja Kyung Kim; Chun Kyon Lee; Young Eun Chon; Kwang-Hyub Han
Journal:  PLoS One       Date:  2016-06-10       Impact factor: 3.240

10.  Screening for Liver Fibrosis and Steatosis in a Large Cohort of Patients with Type 2 Diabetes Using Vibration Controlled Transient Elastography and Controlled Attenuation Parameter in a Single-Center Real-Life Experience.

Authors:  Ioan Sporea; Ruxandra Mare; Alina Popescu; Silviu Nistorescu; Victor Baldea; Roxana Sirli; Adina Braha; Alexandra Sima; Romulus Timar; Raluca Lupusoru
Journal:  J Clin Med       Date:  2020-04-06       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.